...
首页> 外文期刊>European Heart Journal: The Journal of the European Society of Cardiology >The association between older age and receipt of care and outcomes in patients with acute coronary syndromes: A cohort study of the Myocardial Ischaemia National Audit Project (MINAP)
【24h】

The association between older age and receipt of care and outcomes in patients with acute coronary syndromes: A cohort study of the Myocardial Ischaemia National Audit Project (MINAP)

机译:急性冠状动脉综合征患者的年龄与护理接受与结局之间的关联:一项针对心肌缺血国家审计项目(MINAP)的队列研究

获取原文
获取原文并翻译 | 示例
           

摘要

Aims Older people increasingly constitute a large proportion of the acute coronary syndrome (ACS) population. We examined the relationship of age with receipt of more intensive management and secondary prevention medicine. Then, the comparative association of intensive management (reperfusion/angiography) over a conservative strategy on time to death was investigated by age. Methods and results Using data from 155 818 patients in the national registry for ACS in England and Wales [the Myocardial Ischaemia National Audit Project (MINAP)], we found that older patients were incrementally less likely to receive secondary prevention medicines and intensive management for both ST-elevation myocardial infarction (STEMI) and non-ST elevation myocardial infarction (NSTEMI). In STEMI patients ≥85 years, 55% received reperfusion compared with 84% in those aged 18 to <65 [odds ratio 0.22 (95% CI 0.21, 0.24)]. Not receiving intensive management was associated with worse survival [mean follow-up 2.29 years (SD 1.42)] in all age groups (adjusted for sex, cardiovascular risk factors, co-morbidities, healthcare factors, and case severity), but there was an incremental reduction in survival benefit from intensive management with increasing age. In STEMI patients aged 18-64, 65-74, 75-84, and ≥85, adjusted hazard ratios (HRs) for all-cause mortality comparing conservative treatment to intensive management were 1.98 (1.78, 2.19), 1.65 (1.51, 1.80), 1.62 (1.52, 1.72), and 1.36 (1.27, 1.47), respectively. In NSTEMI patients, the respective HRs were 4.37 (4.00, 4.78), 3.76 (3.54, 3.99), 2.79 (2.67, 2.91), and 1.90 (1.77, 2.04). Conclusion We found an incremental reduction in the use of evidence-based therapies with increasing age using a national ACS registry cohort. While survival benefit from more intensive management reduced with older age, better survival was associated with intensive management at all ages highlighting the requirement to improve standard of care in older patients with ACS.
机译:目的老年人在急性冠脉综合征(ACS)人口中所占比例越来越大。我们研究了年龄与接受更深入的管理和二级预防药物的关系。然后,按年龄调查了在死后的保守治疗策略上进行强化管理(再灌注/血管造影)的比较关联。方法和结果使用来自英格兰和威尔士ACS国家注册中心155 818例患者的数据[心肌缺血国家审计项目(MINAP)],我们发现,老年患者接受这两种药物的二级预防药物和强化治疗的可能性逐渐降低ST抬高型心肌梗塞(STEMI)和非ST抬高型心肌梗塞(NSTEMI)。在≥85岁的STEMI患者中,55%接受了再灌注,而在18岁至<65岁的患者中则为84%[几率0.22(95%CI 0.21,0.24)]。在所有年龄组中(未按性别,心血管疾病危险因素,合并症,医疗保健因素和病例严重性进行校正),未接受强化治疗会导致较差的生存期[平均随访时间2.29年(SD 1.42)],但是存在随着年龄的增长,强化管理将使生存率的逐步降低。在18-64岁,65-74岁,75-84岁和≥85岁的STEMI患者中,与保守治疗和强化治疗相比,全因死亡率的调整后危险比(HRs)为1.98(1.78,2.19),1.65(1.51,1.80) ),1.62(1.52、1.72)和1.36(1.27、1.47)。在NSTEMI患者中,各自的HR为4.37(4.00,4.78),3.76(3.54,3.99),2.79(2.67、2.91)和1.90(1.77,2.04)。结论我们发现,使用全国性ACS注册研究队列的患者,随着年龄的增长,循证疗法的使用逐渐减少。尽管随着年龄的增长,强化治疗的生存益处会降低,但更好的存活率与各个年龄段的强化治疗有关,这凸显了提高老年ACS患者护理水平的需求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号